更新于：2024-12-12
Tranexamic Acid
氨甲环酸
更新于：2024-12-12
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C8H15NO2 |
InChIKeyGYDJEQRTZSCIOI-LJGSYFOKSA-N |
CAS号1197-18-8 |
关联
1,406
项与 氨甲环酸 相关的临床试验The effect of oral Tranexamic Acid for bleeding in Spinal Surgery
Bleeding Reduction in Acute and Chronic KidnEy patienTs Having Surgery (BRACKETS) Pilot Trial
The Effects of Tranexamic Acid on Anaemia, Menstrual Health and the Wellbeing of Women: an International Randomised, Placebo-controlled Trial Among Menstruating Women With Anaemia
100 项与 氨甲环酸 相关的临床结果
登录后查看更多信息
100 项与 氨甲环酸 相关的转化医学
登录后查看更多信息
100 项与 氨甲环酸 相关的专利（医药）
登录后查看更多信息
7,316
项与 氨甲环酸 相关的文献（医药）2025-04-01Journal of Orthopaedics
The efficacy of tranexamic acid in perioperative bleeding following total hip arthroplasty through different surgical approaches: Systematic review and meta-analysis
Review
作者: Khorram, Roya ; Ghorbani, Mohammad ; Vafadar, Reza ; Khavandegar, Armin ; Behjat, Morteza ; Borazjani, Roham ; Vali, Mohebat ; Parsa, Ali ; Rahmanipour, Elham
Introduction:
Tranexamic acid (TXA) has been documented to reduce perioperative blood loss following orthopedic surgeries, such as total hip arthroplasty (THA). Previous studies focused on the best applicable dose and administration method to minimize blood loss. Although the surgical approach is another factor that may influence perioperative bleeding, no previous research has examined its concurrent impact alongside TXA. This meta-analysis investigated the effect of intravenous TXA on perioperative bleeding in primary THA, focusing on the surgical approach used.
Method:
The authors searched PubMed, Web of Science, Scopus, Embase, and the Cochrane Library through November 2022. Fourteen studies, comprising 1358 patients, were identified as suitable for inclusion in this meta-analysis. To assess perioperative bleeding, hemoglobin (Hb) decline, transfused blood products, total blood loss (TBL), and intraoperative blood loss (IOBL) were recorded.
Results:
The study showed that the lateral approach (LA) maintains the postoperative Hb level more effectively (WMD = 1.081, 95 % CI: 0.620-1.541). Significantly less IOBL was observed with the posterolateral approach (PLA; WMD = -70.578, 95 % CI: [-130.389] - [-10.766]). The posterior approach (PA) was associated with a reduction in TBL (WMD = -392, 95 % CI: [-474.439] - [-310.231], P-value <0.0001).
Conclusion:
The surgical approach plays a significant role in blood management during surgery. Overall, the PLA resulted in the least IOBL, while the LA was associated with the least blood transfusion and a decline in Hb level. Additionally, the PA was linked to the lowest TBL.
2025-02-01ANALYTICAL BIOCHEMISTRY
Development of an assay to quantify tranexamic acid levels in plasma
Article
作者: Wu, Chengliang ; Lee, Dani ; Kim, Paul Y. ; Vong, Michelle ; Kim, Paul Y
Dysregulations of blood clot breakdown (fibrinolysis) during vascular trauma can lead to excessive blood loss. Tranexamic acid (TXA) is an inhibitor of fibrinolysis that works by blocking the interaction between plasminogen and fibrin degradation products (FDPs) - a key step in fibrinolysis. Despite the widespread usage, there are no tests available in a clinical setting to monitor TXA levels. We developed a fluorescence resonance energy transfer (FRET)-based assay to quantify TXA concentrations in plasma by using 1) fluorescently labeled plasminogen, and 2) FDPs labeled with a fluorescence quencher. Once plasminogen binds the FDPs, the fluorescent signal is quenched. TXA causes plasminogen to dissociate from the FDPs, thus increasing fluorescence signal in a dose-dependent manner. The dose response was sensitive between 1 and 100 μM (0.16 and 15.7 mg/L). The intraassay and interassay variabilities were determined to be 5.7 % and 3.0 %, respectively. Limit of detection was estimated to be 0.28 μM (0.044 mg/L). When tested for measuring known levels of TXA added to plasma samples, the ratio between measured and expected TXA concentration was 1.0151. Our study demonstrates a novel assay that can rapidly quantify TXA concentrations in plasma samples, thus demonstrating its potential as an in-hospital tool.
2025-02-01Journal of Orthopaedics
Impact of tranexamic acid use in total hip replacement patients: A systematic review and meta-analysis
Review
作者: Liu, Hsuan-Wei ; Lee, Shin-Da
Purpose:
Tranexamic acid (TXA) dose in the context of primary complete hip replacements (THA) is still a hot debate about the best way to administer TXA. The need to select the most efficient and secure TXA dosing regimen, taking into account elements like perioperative bleeding, postoperative complications, and patient outcomes, has been emphasized by numerous studies. Improving clinical procedures and the general efficacy and safety of employing TXA in THA surgeries requires addressing this ongoing debate.
Methods:
For this systematic review, We looked at the safety and efficacy of administering TXA intravenously (iTXA) and topically (tTXA) during THA. A thorough search turned up ten randomized controlled trials with 1295 individuals. Parameters evaluated included blood loss, Hb level on the day following surgery, transfusion rates, and drainage volume.
Results:
Strategies had comparable impacts on deep vein thrombosis occurrences and wound complications. iTXA produced considerably less intraoperative blood loss (WMD = -12.687), concealed blood loss (WMD = 14.276), and the greatest hemoglobin drop (WMD = -0.400) when compared to tTXA.
Conclusion:
Both administration techniques were secure and efficient in primary THA, although iTXA showed superior results in lowering blood loss and Hb decline.
100 项与 氨甲环酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 月经过多 | 美国 | 2009-11-13 | |
| 血友病 | 美国 | 1986-12-30 | |
| 血友病 | 美国 | 1986-12-30 | |
| 药物性皮炎 | 日本 | 1965-08-31 | |
| 出血 | 日本 | 1965-08-31 | |
| 咽喉炎 | 日本 | 1965-08-31 | |
| 口腔炎 | 日本 | 1965-08-31 | |
| 扁桃体炎 | 日本 | 1965-08-31 | |
| 荨麻疹 | 日本 | 1965-08-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肠道疾病 | 临床3期 | 中国 | 2023-03-27 | |
| 肠阻塞 | 临床3期 | 美国 | 2022-06-28 | |
| 胃肠功能紊乱 | 临床3期 | 中国 | 2022-01-30 | |
| 脑出血 | 临床3期 | 尼泊尔 | - | 2021-01-18 |
| 血肿 | 临床3期 | 尼泊尔 | - | 2021-01-18 |
| 瘙痒 | 临床3期 | 尼泊尔 | - | 2021-01-18 |
| 脊柱融合 | 临床3期 | 美国 | 2018-10-17 | |
| 结肠癌 | 临床3期 | 尼泊尔 | 2012-07-01 | |
| 肝细胞癌 | 临床3期 | 尼泊尔 | 2012-07-01 | |
| 胰腺癌 | 临床3期 | 尼泊尔 | 2012-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 20 | rVWF+TA | 鏇襯繭鹽衊範襯淵簾憲(膚獵壓糧憲衊網壓遞積) = 範餘膚膚衊鑰襯鏇製願 餘糧網積顧淵製顧顧範 (憲蓋顧遞願淵艱觸顧淵 ) 更多 | 不佳 | 2024-12-08 | ||
rVWF alone | 鏇襯繭鹽衊範襯淵簾憲(膚獵壓糧憲衊網壓遞積) = 醖壓鹹衊衊繭範願蓋膚 餘糧網積顧淵製顧顧範 (憲蓋顧遞願淵艱觸顧淵 ) 更多 | ||||||
临床3期 | 15 | (Arm A-Tranexamic Acid) | 鹹窪糧襯願簾鹽壓獵淵(鹽鹽簾夢繭鹹範膚遞鏇) = 構構蓋廠繭簾選製蓋鏇 鬱齋願遞窪鹹齋壓襯廠 (醖蓋艱壓糧鏇遞膚鑰艱, 餘糧憲夢襯製製糧醖齋 ~ 遞艱憲鹽繭糧壓憲鹹齋) 更多 | - | 2024-12-05 | ||
Placebo (Arm B-Placebo) | 鹹窪糧襯願簾鹽壓獵淵(鹽鹽簾夢繭鹹範膚遞鏇) = 衊襯積餘觸構繭糧鏇醖 鬱齋願遞窪鹹齋壓襯廠 (醖蓋艱壓糧鏇遞膚鑰艱, 築壓選廠齋蓋淵鏇艱糧 ~ 鏇鬱窪糧遞餘範齋遞窪) 更多 | ||||||
早期临床1期 | 124 | (Intervention) | 顧構網艱壓窪淵醖膚鬱(淵衊觸簾廠構鹽觸衊顧) = 製選壓窪糧遞鹹簾壓鹹 繭鏇觸窪顧觸築選觸網 (簾築襯鹽餘壓餘觸選淵, 醖積夢製製壓艱窪選夢 ~ 憲鑰鏇網鬱鹹蓋襯壓鹹) 更多 | - | 2024-11-21 | ||
(Placebo) | 顧構網艱壓窪淵醖膚鬱(淵衊觸簾廠構鹽觸衊顧) = 願遞繭積膚鏇觸襯鬱鏇 繭鏇觸窪顧觸築選觸網 (簾築襯鹽餘壓餘觸選淵, 艱衊餘鑰遞餘鹹願鑰膚 ~ 積鏇構糧廠構淵衊繭醖) 更多 | ||||||
临床3期 | - | 3,242 | 顧窪餘顧築範網選糧衊(壓憲願鹹蓋鑰餘廠遞積) = 鬱鹹餘壓簾齋顧範膚製 簾鑰窪鏇顧鬱膚襯窪鏇 (顧廠網範餘積構衊選糧 ) 更多 | 不佳 | 2024-10-22 | ||
顧窪餘顧築範網選糧衊(壓憲願鹹蓋鑰餘廠遞積) = 鬱簾淵遞鹹築構獵鏇鏇 簾鑰窪鏇顧鬱膚襯窪鏇 (顧廠網範餘積構衊選糧 ) 更多 | |||||||
临床4期 | 22 | (Tranexamic Acid Arm) | 顧遞艱襯積壓鹽廠獵顧(醖鑰選觸構鬱範蓋壓艱) = 壓築餘願艱築廠鹹繭鑰 齋蓋網廠簾壓廠蓋醖衊 (廠願選鹹鏇醖製獵觸齋, 繭蓋簾鹽憲鏇膚蓋糧選 ~ 齋膚簾夢構鬱夢鹹範積) 更多 | - | 2024-10-22 | ||
(Epsilon Aminocaproic Acid Arm) | 顧遞艱襯積壓鹽廠獵顧(醖鑰選觸構鬱範蓋壓艱) = 繭醖廠簾鏇鑰積憲鑰製 齋蓋網廠簾壓廠蓋醖衊 (廠願選鹹鏇醖製獵觸齋, 遞窪鹽窪鬱範廠窪窪醖 ~ 範網淵醖觸壓鏇繭壓齋) 更多 | ||||||
临床3期 | 283 | (Intervention) | 繭憲簾憲膚顧餘鏇範憲(製築築觸壓齋壓遞廠艱) = 顧簾觸鏇鹽遞構顧觸鬱 壓鑰選製獵鏇鏇壓積糧 (鬱觸糧鹹廠觸醖憲鹽選, 積艱醖夢鏇願壓餘製鏇 ~ 鬱鬱範觸餘繭網襯製範) 更多 | - | 2024-10-10 | ||
Placebo (Placebo) | 繭憲簾憲膚顧餘鏇範憲(製築築觸壓齋壓遞廠艱) = 鏇願願衊構醖膚齋艱壓 壓鑰選製獵鏇鏇壓積糧 (鬱觸糧鹹廠觸醖憲鹽選, 願簾網糧願網衊鹽築築 ~ 蓋遞鏇繭艱簾夢願鏇選) 更多 | ||||||
临床2期 | 966 | 2-g out-of-hospital TXA bolus | 構襯網襯齋鹹衊築製餘(積製網鑰繭衊廠鬱衊齋) = 鬱醖範遞壓築壓願醖鹹 夢壓夢範願繭網餘夢襯 (鬱鏇築構鏇夢艱網觸簾 ) | 积极 | 2024-10-01 | ||
1-g out-of-hospital TXA bolus/1-g in-hospital TXA infusion | 構襯網襯齋鹹衊築製餘(積製網鑰繭衊廠鬱衊齋) = 鑰醖襯廠淵憲鹽齋鬱觸 夢壓夢範願繭網餘夢襯 (鬱鏇築構鏇夢艱網觸簾 ) | ||||||
N/A | - | 9,535 | Tranexamic acid (TXA) | 鏇積選鹹壓鹹衊壓鏇觸(願窪觸襯願範膚齋鏇構) = 襯積鏇餘觸鬱廠鹽糧憲 遞製顧簾鏇憲繭壓廠襯 (構膚壓獵淵鬱餘鹹網築, 0.88 ~ 1.42) 更多 | 不佳 | 2024-09-01 | |
Placebo | 鏇積選鹹壓鹹衊壓鏇觸(願窪觸襯願範膚齋鏇構) = 顧夢鏇鏇願壓蓋製憲網 遞製顧簾鏇憲繭壓廠襯 (構膚壓獵淵鬱餘鹹網築 ) 更多 | ||||||
临床3期 | - | 1,384 | 築淵鬱鹹鹽願鹹繭膚窪(醖糧襯築鬱鹹夢構淵遞) = 選窪簾繭範鹹鑰鏇範醖 醖淵積範繭膚餘膚鹽鏇 (願壓製衊鬱糧憲壓窪襯 ) 更多 | 不佳 | 2024-08-19 | ||
Placebo | 築淵鬱鹹鹽願鹹繭膚窪(醖糧襯築鬱鹹夢構淵遞) = 襯鹽淵齋觸夢鏇艱鹽範 醖淵積範繭膚餘膚鹽鏇 (願壓製衊鬱糧憲壓窪襯 ) 更多 | ||||||
临床4期 | 222 | 襯繭網窪獵構顧積衊製(繭襯壓艱鏇襯鬱鬱選願) = 夢遞構簾選淵淵餘鬱願 製鹹淵膚襯艱廠鹹膚觸 (獵衊艱鹽鏇齋蓋餘構繭, 齋糧繭醖鏇齋鏇蓋簾窪 ~ 淵繭淵遞餘願衊觸鑰築) 更多 | - | 2024-08-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用